2025年以来,创新药板块强势突围,成为成长赛道中的最大“黑马”。Wind数据显示,截至7月9日,全市场成立满一年的963只ETF中,仅有7只实现业绩翻倍,港股创新药ETF(513120)便是其中之一,该基金近一年来的收益率达到103%(截至7月11日)。图片来源:东方财富截图 从产业角度看,随着近年来全球医药巨头加快在华“扫货”的节奏,我国生物技术(Biotech)企业的BD(商务拓展)交易...
Source Link2025年以来,创新药板块强势突围,成为成长赛道中的最大“黑马”。Wind数据显示,截至7月9日,全市场成立满一年的963只ETF中,仅有7只实现业绩翻倍,港股创新药ETF(513120)便是其中之一,该基金近一年来的收益率达到103%(截至7月11日)。图片来源:东方财富截图 从产业角度看,随着近年来全球医药巨头加快在华“扫货”的节奏,我国生物技术(Biotech)企业的BD(商务拓展)交易...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.